VNR was administered on day 1 and 8, and CDDP and MMC on day 1. The second course was started after 4 weeks and the further courses were repeated every 6 weeks. In phase I, leukopenia was considered to be dose-limiting toxicity. In level 4 (VNR 25 mg/m2, CDDP 80 mg/m2, MMC 8...
Vinorelbine (VNR), ifosfamide (IFO) and cisplatin (CDDP) as assitencial treatment in patients (PTS) with inoperable non small cell lung cancer (NSCLC)Publication » Vinorelbine (VNR), ifosfamide (IFO) and cisplatin (CDDP) as assitencial treatment in patients (PTS) with inoperable non small ...
Vinorelbine (VNR), ifosfamide (IFO) and cisplatin (CDDP) as assitencial treatment in patients (PTS) with inoperable non small cell lung cancer (NSCLC)doi:10.1016/s0169-5002(00)80180-4Montalar, JMorales, SVadell, CMaestu, ITorregrosa, M.D...
A phase II study of induction CDDP+VNR+MMC followed by concomitant-boost thoracic radiotherapy with concurrent daily CDDP for unresectable locally advanced NSCLC (LA-NSCLC): P2-209Methadone maintenancecocaine usedaily activitypatterns of drug use...
205 Phase I鈥揑I study of vinorelbine (VNR), cisplatin (CDDP) and mitomycin C (MMC) in non-small cell lung cancer (NSCLC)OgawaraFuruseNishiwakiTakadaFukuoka
Natale, M.De Cataldis, G.Manzione, L.Bilancia, D.Cioffi, R.European Journal of CancerComella P, Panza N, Frasci G et al (1997) Gemcitabine (GEM)-cisplatin (CDDP)- vinorelbine (VNR) combination in advanced non-small cell lung cancer (NSCLC). A phase II randomized study. Lung Cancer ...
Phase II study of cisplatin (CDDP), ifosfamide (IFX) and vinorelbine (VNR) in stage-IIIB-IV NSCLCdoi:10.1016/0959-8049(94)90813-3E. BaldiniC. TibaldiA. ChellaC.A. AngelettiG. SilvanoP.F. ConteEuropean Journal of Cancer
P-212 Split-dose cisplatin (CDDP) and vinorelbine (VNR) in advanced non-small cell lung cancer (NSCLC): treatment outcomes including health-related quality of life (HRQL)doi:10.1016/S0169-5002(03)92181-7Lee, Christopher W.Murray, Nevin...
Gemcitabine (GEM)-cisplatin (CDDP)-vinorelbine (VNR) combination in advanced non-small cell lung cancer (NSCLC): a phase II randomized study [abstract no. *1615]. Thirty-Third Annual Meeting, American Society of Clinical Oncologists; 1997 May 17–20; Denver, Vol. 16, 449a...
Phase II study of cisplatin (CDDP), ifosfamide (IFX) and vinorelbine (VNR) in stage-IIIB-IV NSCLCdoi:10.1016/0169-5002(94)94203-XE. Baldini and C. Tibaldi and A. Ardizzoni and A. Chella and C.A. Angeletti and G. Silvano and P.F. Conte...